Literature DB >> 10693253

Quality of life in patients with oesophageal cancer.

J M Blazeby1, D Alderson, J R Farndon.   

Abstract

There is a growing interest in assessing quality of life in patients with oesophageal cancer because it provides detailed information of the patients' perception of the benefits or harms of treatment. Yet few studies have prospectively measured quality of life using validated appropriate instruments. There are now several questionnaires for patients with cancer, although these are not sufficiently sensitive to small but clinically important changes in quality of life. It is therefore recommended that a disease-specific module is used in conjunction with generic measures. The European Organisation into Research and Treatment of Cancer (EORTC) QLQ-OES24 is currently completing an international validation study. It is used with the EORTC QLQ-C30 core instrument and is designed for patients undergoing potentially curative treatment or palliation of malignant dysphagia. Studies that have assessed quality of life after oesophagectomy have generally found that survivors do regain their former health. Little is known about the effect of neoadjuvant chemoradiation on patients' quality of life. Following endoscopic palliation of dysphagia, quality of life can be maintained and improvement of swallowing is seen. A validated appropriate assessment of quality of life should be included in future palliative trials and in studies of new treatments which may marginally influence survival but cause significant side effects.

Entities:  

Mesh:

Year:  2000        PMID: 10693253     DOI: 10.1007/978-3-642-59600-1_20

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  5 in total

Review 1.  Survival after oesophagectomy for cancer of the oesophagus.

Authors:  Hubert J Stein; Burkhard H A von Rahden; J Rüdiger Siewert
Journal:  Langenbecks Arch Surg       Date:  2004-07-14       Impact factor: 3.445

2.  Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?

Authors:  Karin Ribi; Dieter Koeberle; Jan C Schuller; Hanspeter Honegger; Arnaud Roth; Viviane Hess; Peter Moosmann; Roger von Moos; Markus Borner; Norbert Lombriser; Bernhard Pestalozzi; Thomas Ruhstaller
Journal:  Support Care Cancer       Date:  2009-02-07       Impact factor: 3.603

3.  Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences.

Authors:  A G E M de Boer; P F M Stalmeier; M A G Sprangers; J C J M de Haes; J W van Sandick; J B F Hulscher; J J B van Lanschot
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

4.  Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.

Authors:  J Rees; C N Hurt; S Gollins; S Mukherjee; T Maughan; S J Falk; J Staffurth; R Ray; N Bashir; J I Geh; D Cunningham; R Roy; J Bridgewater; G Griffiths; L S Nixon; J M Blazeby; T Crosby
Journal:  Br J Cancer       Date:  2015-07-23       Impact factor: 7.640

5.  What surgeons tell patients and what patients want to know before major cancer surgery: a qualitative study.

Authors:  Angus G K McNair; F MacKichan; J L Donovan; S T Brookes; K N L Avery; S M Griffin; T Crosby; J M Blazeby
Journal:  BMC Cancer       Date:  2016-03-31       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.